1
0
0
News
History of Changes for Study: NCT ClinicalTrials.govclassic.clinicaltrials.gov › history › NCT
classic.clinicaltrials.gov
Contact:Contact: Anne-Katrin Maly Ext Open or close this module IPDSharing. Plan to Share IPD: Open or close ...
Netzwerk-Profile
LinkedIn: Anne-Katrin Maly – Deutschland | Berufsprofil - LinkedInde.linkedin.com › anne-katrin-maly
Sehen Sie sich das Profil von Anne-Katrin Maly auf LinkedIn an. Als weltweit größtes Business-Netzwerk hilft LinkedIn Menschen wie Anne-Katrin Maly dabei, ...
Business-Profile
Xing: Anne-Katrin Maly - Head of Clinical DevelopmentXING
Anne-Katrin Maly, Mannheim Berufserfahrung, Kontaktdaten, Portfolio und weitere Infos: Erfahr mehr – oder kontaktier Anne-Katrin Maly direkt bei XING.
Dokumente zum Namen
Broad inter‐individual variations in circulating progenitor cell ...Stem Cells Journals
stemcellsjournals.onlinelibrary.wiley.com
von AW Roberts · · Zitiert von: 79 — ... Anne-Katrin Maly, Karl Ernst Siegler, Kai Mehltretter, Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed ... von AW Roberts · · Zitiert von: 79 — ... Anne-Katrin Maly, Karl Ernst Siegler, Kai Mehltretter, Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed ...
Wissenschaftliche Veröffentlichungen
GlycoPEGylated Filgrastim XM22 Demonstrates Dose ...ScienceDirect.com
www.sciencedirect.com
von H Lubenau · — ... Anne-Katrin Maly,1* Michael Seiberling, MD2* 1Clinical Development, BioGeneriX AG, Mannheim, Germany 2Clinical Pharmacology, Swiss Pharma Contract ... von H Lubenau · — ... Anne-Katrin Maly,1* Michael Seiberling, MD2* 1Clinical Development, BioGeneriX AG, Mannheim, Germany 2Clinical Pharmacology, Swiss Pharma Contract ...
GlycoPEGylated Filgrastim XM22 Fixed Dose ...ScienceDirect.com
www.sciencedirect.com
von H Lubenau · — ... Anne-Katrin Maly,1* Michael Seiberling, MD2* 1Clinical Development, BioGeneriX AG, Mannheim, Germany 2Clinical Pharmacology, Swiss Pharma ... von H Lubenau · — ... Anne-Katrin Maly,1* Michael Seiberling, MD2* 1Clinical Development, BioGeneriX AG, Mannheim, Germany 2Clinical Pharmacology, Swiss Pharma ...
Veröffentlichungen allgemein
pdfSpringer
link.springer.com
von H Lubenau · · Zitiert von: 74 — Dr Heinz Lubenau and Anne-Katrin Maly are employees of BioGeneriX. AG, Mannheim, Germany. Dr Peter Bias is an employee of Merckle. GmbH, Ulm, Germany, which ... von H Lubenau · · Zitiert von: 74 — Dr Heinz Lubenau and Anne-Katrin Maly are employees of BioGeneriX. AG, Mannheim, Germany. Dr Peter Bias is an employee of Merckle. GmbH, Ulm, Germany, which ...
Pharmacokinetic and Pharmacodynamic Profile of New ...ResearchGate
www.researchgate.net
Anne-Katrin Maly · Anne-Katrin Maly. This person is not on ResearchGate, or hasn't claimed this research yet.
Sonstiges
Anne-Katrin Maly's scientific contributions - ResearchGate
www.researchgate.net
Anne-Katrin Maly's 4 research works with 99 citations and 191 reads, including: Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim ...
IDCrawl
www.idcrawl.com
Anne-Katrin Maly · Dept of German & Russian Newsletter Fall · Untitled · 2017_CFHC_AR_horizontal (2).indd · GroupSense · Obituary Guestbook. Instagram.
2024 Mmh maly4stress.pl
4stress.pl
This is how Anne-Katrin Maly summarized her experience...Free Beats https://www.youtube.com/watch?v=fM7_nyo4wIQ&list=RDMMfM7_nyo4wIQ&index=1https://www ...
The ISHAGE Guidelines for CD34+ Cell Determination by ...Mary Ann Liebert, Inc.
www.liebertpub.com
Heinz Lubenau, Peter Bias, Anne-Katrin Maly, Karl Ernst Siegler, Kai Mehltretter Pharmacokinetic and. Pharmacodynamic Profile of New Biosimilar ...
GlycoPEGylated Filgrastim XM22 Fixed Dose Demonstrates Similar ...ashpublications.org
ashpublications.org
Anne-Katrin Maly,. Anne-Katrin Maly *. 1Clinical Development, BioGeneriX AG, Mannheim, Germany. (Intr. by David A. Zopf). Search for other works by this author ... Anne-Katrin Maly,. Anne-Katrin Maly *. 1Clinical Development, BioGeneriX AG, Mannheim, Germany. (Intr. by David A. Zopf). Search for other works by this author ...
single-blind, randomized, crossover trialNational Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von H Lubenau · · Zitiert von: 74 — Authors. Heinz Lubenau , Peter Bias, Anne-Katrin Maly, Karl Ernst Siegler, Kai Mehltretter. Affiliation. 1 BioGeneriX AG, Mannheim, Germany. heinz.lubenau@t ... von H Lubenau · · Zitiert von: 74 — Authors. Heinz Lubenau , Peter Bias, Anne-Katrin Maly, Karl Ernst Siegler, Kai Mehltretter. Affiliation. 1 BioGeneriX AG, Mannheim, Germany. heinz.lubenau@t ...
Pharmacokinetic and pharmacodynamic profile of new Galego.gale.com › i.do
go.gale.com
Dr Heinz Lubenau and Anne-Katrin Maly are employees of BioGeneriX AG, Mannheim, Germany. Dr Peter Bias is an employee of Merckle GmbH, Ulm, Germany, ...
RICCARDO WEYLER , Gerente de Desarrollo de Negocios en ...b2b.getemail.io › riccardo-weyler-boeringher-ingelh...
b2b.getemail.io
Get his/her professional email address for free. Anne-katrin Maly. Gerente de Proyectos Clínicos. Get his/her professional email address for free ...
Showing papers in "BioDrugs in 2009" - Typeset.iotypeset.io › Journal Directory › BioDrugs
typeset.io
Heinz Lubenau, Peter Bias, Anne-Katrin Maly, Karl Ernst Siegler, Kai Mehltretter - Show less +1 more. 31 Dec BioDrugs. TL;DR: Both filgrastims showed ...
Stefan Jänich - Clinical Trial Leader - iOMEDICO AG | XINGwww.anmeldens.com › profile
www.anmeldens.com
Anne-Katrin Maly. Clinical Trial Leader. Ingelheim · Beate Niemeier. Clinical research associate. Freiburg · Grant Fischer. Clinical Practice Lead (Europe).
stem cells 检索结果 - 图书馆 - 黑龙江中医药大学lib.hljucm.net › Archive › Search
lib.hljucm.net
作者: Heinz Lubenau.;Peter Bias.;Anne-Katrin Maly.;Karl Ernst Siegler.;Kai Mehltretter. 来源: BioDrugs 年23卷1期43-51页. 申请馆际互借; 第三方免费链接1 第 ...
Verwandte Suchanfragen zu Anne-Katrin Maly
| Heinz Lubenau |
Person "Maly" (4) Vorname "Anne-Katrin" (939) Name "Maly" (496) |
sortiert nach Relevanz / Datum